Full Text View
Tabular View
Study Results
Related Studies
Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants
This study has been completed.
Study NCT01068717   Information provided by Bristol-Myers Squibb

First Received on February 12, 2010.   Last Updated on November 1, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Type 2 Diabetes Mellitus
Additional conditions recognized in this trial
Diabetes Mellitus
Diabetes Mellitus, Type 2
More general conditions related to this trial
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Additional drug interventions recognized in this trial
Metformin
Saxagliptin
More general drug interventions related to this trial
Dipeptidyl-Peptidase IV Inhibitors
Enzyme Inhibitors
Hypoglycemic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Sponsors listed in this trial
Bristol-Myers Squibb
AstraZeneca


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services